Marina Bradley serves as the Director of Finance at Scantibodies Laboratory, Inc., a leading player in the biotech diagnostics sector with a workforce of approximately 1,300 employees and multiple foreign subsidiaries. In her pivotal role, Marina leverages her extensive expertise in both public and private...
Marina Bradley serves as the Director of Finance at Scantibodies Laboratory, Inc., a leading player in the biotech diagnostics sector with a workforce of approximately 1,300 employees and multiple foreign subsidiaries. In her pivotal role, Marina leverages her extensive expertise in both public and private company finance to drive strategic initiatives that enhance operational efficiency and financial performance. Her responsibilities encompass full-cycle accounting, cost accounting, and the preparation of financial statements in compliance with GAAP and IFRS standards, ensuring that the organization maintains robust financial health amid the complexities of global manufacturing.
One of Marina's key projects involves overseeing the financial consolidation and reporting for Scantibodies’ maquiladora operations, which are critical to the company’s supply chain and production capabilities. By implementing advanced budgeting and forecasting techniques, she has successfully identified variances and optimized resource allocation, contributing to significant cost savings and improved profitability. Her proficiency with financial management software, including Epicor, SAP, and Hyperion, allows her to streamline processes and enhance performance metrics, thereby providing valuable insights to executive leadership.
Marina is also deeply involved in ensuring SOX 404 compliance, which is essential for maintaining the integrity of financial reporting and safeguarding the company’s assets. Her commitment to excellence in auditing, revenue recognition, and account reconciliation underscores her role as a trusted advisor within the organization. With a keen eye for detail and a strategic mindset, Marina Bradley continues to play a vital role in shaping the financial landscape of Scantibodies Laboratory, Inc., driving growth and innovation in the biotech industry.
